Corvus Pharmaceuticals, Inc. (CRVS) vs Monte Rosa Therapeutics, Inc. (GLUE)
A side-by-side comparison of Corvus Pharmaceuticals, Inc. and Monte Rosa Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRVS
Corvus Pharmaceuticals, Inc.
$10.57HealthcareDelayed quote: Oct 6, 2026, 11:49 AM EDT
GLUE
Monte Rosa Therapeutics, Inc.
$10.18HealthcareDelayed quote: Oct 6, 2026, 11:50 AM EDT
Total return — CRVS vs GLUE
growth of $100 · dividends reinvested · last 5yCRVS +282.2% (+30.8%/yr)GLUE -51.5% (-13.5%/yr)CRVS compounded faster over this window
Log scale — wide-divergence pair
CRVS GLUE
CRVS vs GLUE: by the numbers
- •CRVS is the larger company ($889M vs $860M market cap).
- •Both run net losses; CRVS's is the smaller (0.00% vs -560.85% net margin).
Metrics side by side
Valuation
| Metric | CRVS | GLUE |
|---|---|---|
| P/S ratio | N/A | 29.94 |
| P/B ratio | 3.94 | 1.76 |
Profitability
| Metric | CRVS | GLUE |
|---|---|---|
| Gross margin | 0.00% | 92.94% |
| Operating margin | 0.00% | -43.83% |
| Net margin | 0.00% | -560.85% |
| ROE | -24.02% | -33.06% |
| ROIC | -25.25% | -28.69% |
Growth (annualized)
| Metric | CRVS | GLUE |
|---|---|---|
| Total return CAGR (5Y) | 17.88% | -12.32% |
Frequently asked
- How have CRVS and GLUE total returns compared?
- Over the past 5 years, CRVS delivered 17.88% and GLUE delivered -12.32% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.